

Gout Market Research Report Forecast till 2030

Market Report | 2023-11-01 | 128 pages | Market Research Future

AVAILABLE LICENSES:

- Single User Price \$4950.00
- Enterprisewide Price \$7250.00

Report description:

Gout Market Research Report Forecast till 2030

Market Overview

Gout Market is anticipated to register a significant CAGR of 11.75% during the review period.

Gout is a kind of provocative joint pain that influences men beyond 40 a year old, have a high measure of uric corrosive in their blood. As per studies, its commonness and frequency have expanded over the most recent couple of many years. The rising commonness of gout because of changing way of life designs and the developing geriatric populace is supposed to help market development over the gauge period. For example, according to the article distributed by the Records of Rheumatic Sickesses in June 2021, a cross country companion concentrates on utilizing information from the Clinical Practice Research Datalink, from 1997 to across the Coronavirus pandemic in 2021 saw that the predominance pace of gout has expanded from 0.98% in 1997 to 2.33% in 2021. Notwithstanding, as per a similar source, the frequency of gout expanded by 0.98/1,000 people in UK 2021. Thusly, the weight of gout is supposed to build the interest in drugs treating this condition, which is expected to impel the market development over the estimate period.

Market Segmentation

The Gout Market segmentation, based on treatment and diagnosis, includes diagnosis, treatment. The treatment segment is further sub segmented into NSAIDs, corticosteroids, colchicine, urate-lowering agents, and others.

The Gout Market segmentation is based on applications that include acute gout and chronic gout. The Gout Market segmentation is based on hospitals & clinics, specialty centers, and others.

Regional Insights

The North America region fragmented into US, and Canada. The North America region held the biggest market share in the Gout Endlessly market is represented USD 1.80 billion of every 2022 and is supposed to display a 12.03% CAGR during the review time frame. Further, in the North America region the US gout market represented the biggest market share. This is credited to the rising predominance of gout, developing reception of biologics, and rising Research and development exercises on regenerative prescriptions.

Europe gout market is supposed to represent the second-biggest market share because of the availability to cutting edge finding and treatment offices, the rising geriatric populace inclined to gout is driving up interest for powerful treatment and therapeutics and developing medical care consumption. The Asia-Pacific gout market is supposed to develop at a CAGR of 13.12% from 2023 to

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

2030. This is because of variables like further developing medical care framework, developing speculation by central parts with neighbourhood producers, and the rising patient populace experiencing gout.

The Rest of the World incorporates the Middle East, Africa, and Latin America. Middle East hold the significant market share in middle east and Africa region because of restricted medical care framework, a shortage of mindfulness regarding the side effects of the sickness, and an absence of talented experts to make gout therapeutics drugs are restricting the development of the gout market in Sub-Saharan Africa.

Major Players

Key Companies in the Gout Market are Novartis AG (Switzerland), Lannett (US), Horizon Therapeutics plc (US), Takeda Pharmaceutical Company Limited (Japan), GlaxoSmithKline plc (UK), Regeneron Pharmaceuticals, Inc (US), Teijin Limited (Japan), Viatris Inc (US), Boehringer Ingelheim International GmbH (Germany), and ROME Therapeutics, LLC (US).

Table of Contents:

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY 13

1.1 OVERVIEW 13

2 MARKET INTRODUCTION 14

2.1 DEFINITION 14

2.2 SCOPE OF THE STUDY 14

2.3 RESEARCH OBJECTIVE 14

2.4 MARKET STRUCTURE 15

2.5 ASSUMPTIONS & LIMITATIONS 15

3 RESEARCH METHODOLOGY 16

3.1 DATA MINING 16

3.2 SECONDARY RESEARCH 17

3.3 PRIMARY RESEARCH 18

3.4 BREAKDOWN OF PRIMARY RESPONDENTS 19

3.5 FORECASTING TECHNIQUES 20

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 21

3.6.1 BOTTOM-UP APPROACH 22

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

3.6.2 TOP-DOWN APPROACH 22

3.7 DATA TRIANGULATION 23

3.8 VALIDATION 23

4 MARKET DYNAMICS 24

4.1 OVERVIEW 24

4.2 DRIVERS 25

4.2.1 INCREASING PREVALENCE OF GOUT 25

4.2.2 RISING HEALTHCARE EXPENDITURE 25

4.2.3 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES 26

4.3 RESTRAINTS 27

4.3.1 SIDE EFFECTS OF GOUT THERAPEUTIC DRUGS 27

4.3.2 LACK OF AWARENESS AMONG PEOPLE 28

4.4 OPPORTUNITY 28

4.4.1 RISING NUMBER OF STRATEGIC INITIATIVES 28

5 MARKET FACTOR ANALYSIS 29

5.1 VALUE CHAIN ANALYSIS 29

5.1.1 R&D 30

5.1.2 MANUFACTURING 30

5.1.3 DISTRIBUTION & SALES 30

5.1.4 POST-SALES MONITORING 30

5.2 PORTER'S FIVE FORCES MODEL 31

5.2.1 THREAT OF NEW ENTRANTS 31

5.2.2 BARGAINING POWER OF SUPPLIERS 32

5.2.3 THREAT OF SUBSTITUTES 32

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.2.4 BARGAINING POWER OF BUYERS 32

5.2.5 INTENSITY OF RIVALRY 32

5.3 IMPACT OF COVID-19 ON THE GLOBAL GOUT MARKET 33

5.3.1 IMPACT ON VALUE CHAIN 33

5.3.2 IMPACT ON SUPPLY CHAIN 33

5.3.3 IMPACT ON KEY PLAYERS 33

6 GLOBAL GOUT MARKET, BY DIAGNOSIS & TREATMENT 34

6.1 OVERVIEW 34

6.2 DIAGNOSIS 36

6.3 TREATMENT 36

6.3.1 NSAIDS 37

6.3.2 CORTICOSTEROIDS 37

6.3.3 COLCHICINE 38

6.3.4 URATE-LOWERING AGENTS 38

6.3.5 OTHERS 39

7 GLOBAL GOUT MARKET, BY APPLICATION 40

7.1 OVERVIEW 40

7.2 ACUTE GOUT 41

7.3 CHRONIC GOUT 42

8 GLOBAL GOUT MARKET, BY END USER 43

8.1 OVERVIEW 43

8.2 HOSPITALS & CLINICS 44

8.3 SPECIALTY CENTERS 45

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

8.4 OTHERS 45

9 GLOBAL GOUT MARKET, BY REGION 46

9.1 OVERVIEW 46

9.2 NORTH AMERICA 48

9.2.1 US 50

9.2.2 CANADA 51

9.3 EUROPE 52

9.3.1 GERMANY 54

9.3.2 UK 55

9.3.3 FRANCE 56

9.3.4 ITALY 57

9.3.5 SPAIN 58

9.3.6 REST OF EUROPE 59

9.4 ASIA-PACIFIC 61

9.4.1 CHINA 63

9.4.2 JAPAN 64

9.4.3 INDIA 65

9.4.4 AUSTRALIA 66

9.4.5 SOUTH KOREA 67

9.4.6 REST OF ASIA PACIFIC 68

9.5 REST OF THE WORLD 69

9.5.1 MIDDLE EAST 71

9.5.2 AFRICA 72

9.5.3 LATIN AMERICA 73

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

10 COMPETITIVE LANDSCAPE 74

10.1 OVERVIEW 74

10.2 COMPETITIVE BENCHMARKING 75

10.3 MAJOR GROWTH STRATEGY IN THE GLOBAL GOUT MARKET 76

10.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL GOUT MARKET 77

10.5 KEY DEVELOPMENT ANALYSIS 77

10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES 78

10.6.1 PRODUCT LAUNCH/ PRODUCT APPROVAL 78

10.6.2 PARTNERSHIPS/ AGREEMENTS 78

10.7 FINANCIAL MATRIX 78

10.7.1 SALES (USD MILLION), 2022 78

10.7.2 RESEARCH & DEVELOPMENT EXPENDITURE (USD MILLION), 2022 79

11 COMPANY PROFILES 80

11.1 NOVARTIS AG 80

11.1.1 COMPANY OVERVIEW 80

11.1.2 FINANCIAL OVERVIEW 81

11.1.3 PRODUCTS OFFERED 81

11.1.4 KEY DEVELOPMENTS 81

11.1.5 SWOT ANALYSIS 82

11.1.6 KEY STRATEGIES 82

11.2 LANNETT 83

11.2.1 COMPANY OVERVIEW 83

11.2.2 FINANCIAL OVERVIEW 83

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

11.2.3 PRODUCTS OFFERED	84
11.2.4 KEY DEVELOPMENTS	84
11.2.5 KEY STRATEGIES	84
11.3 HORIZON THERAPEUTICS PLC	85
11.3.1 COMPANY OVERVIEW	85
11.3.2 FINANCIAL OVERVIEW	86
11.3.3 PRODUCTS OFFERED	86
11.3.4 KEY DEVELOPMENTS	86
11.3.5 KEY STRATEGIES	87
11.4 TAKEDA PHARMACEUTICAL COMPANY LIMITED	88
11.4.1 COMPANY OVERVIEW	88
11.4.2 FINANCIAL OVERVIEW	88
11.4.3 PRODUCTS OFFERED	89
11.4.4 KEY DEVELOPMENTS	89
11.4.5 KEY STRATEGIES	89
11.5 GLAXOSMITHKLINE PLC	90
11.5.1 COMPANY OVERVIEW	90
11.5.2 FINANCIAL OVERVIEW	91
11.5.3 PRODUCTS OFFERED	91
11.5.4 KEY DEVELOPMENTS	91
11.5.5 SWOT ANALYSIS	92
11.5.6 KEY STRATEGIES	92
11.6 REGENERON PHARMACEUTICALS, INC.	93
11.6.1 COMPANY OVERVIEW	93

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

11.6.2 FINANCIAL OVERVIEW	93
11.6.3 PRODUCTS OFFERED	94
11.6.4 KEY DEVELOPMENTS	94
11.6.5 KEY STRATEGIES	94
11.7 TEIJIN LIMITED	95
11.7.1 COMPANY OVERVIEW	95
11.7.2 FINANCIAL OVERVIEW	95
11.7.3 PRODUCTS OFFERED	96
11.7.4 KEY DEVELOPMENTS	96
11.7.5 SWOT ANALYSIS	96
11.7.6 KEY STRATEGIES	96
11.8 VIATRIS INC.	97
11.8.1 COMPANY OVERVIEWS	97
11.8.2 FINANCIAL OVERVIEW	98
11.8.3 PRODUCTS OFFERED	98
11.8.4 KEY DEVELOPMENTS	98
11.8.5 SWOT ANALYSIS	99
11.8.6 KEY STRATEGIES	99
11.9 BOEHRINGER INGELHEIM INTERNATIONAL GMBH.	100
11.9.1 COMPANY OVERVIEW	100
11.9.2 FINANCIAL OVERVIEW	101
11.9.3 PRODUCTS OFFERED	101
11.9.4 KEY DEVELOPMENTS	102

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

11.9.5 SWOT ANALYSIS	102
11.9.6 KEY STRATEGIES	102
11.10 ROMEG THERAPEUTICS, LLC	103
11.10.1 COMPANY OVERVIEW	103
11.10.2 FINANCIAL OVERVIEW	103
11.10.3 PRODUCTS OFFERED	103
11.10.4 KEY DEVELOPMENTS	103
11.10.5 KEY STRATEGIES	103
12 APPENDIX	104
12.1 REFERENCES	104
12.2 WORLD HEALTH ORGANIZATION	104
12.3 THE GOUT EDUCATION SOCIETY	104
12.4 ARTHRITIS FOUNDATION	104
12.5 AMERICAN ARTHRITIS SOCIETY	104
12.6 SOUTH AFRICAN RHEUMATISM AND ARTHRITIS ASSOCIATION (SARAA)	104
12.7 EMIRATES ARTHRITIS FOUNDATION	104
12.8 ARTHRITIS FOUNDATION OF ASIA	104
12.9 OSTEOARTHRITIS RESEARCH SOCIETY INTERNATIONAL (OARSI)	104
12.10 SOAR - SOCIETY FOR OSTEOARTHRITIS RESEARCH	104
12.11 THE EUROPEAN ALLIANCE OF ASSOCIATIONS FOR RHEUMATOLOGY	104
12.12 RELATED REPORTS	105

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Gout Market Research Report Forecast till 2030

Market Report | 2023-11-01 | 128 pages | Market Research Future

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User Price	\$4950.00
	Enterprisewide Price	\$7250.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-13"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com